Janux Therapeutics Inc (NASDAQ: JANX) on Monday, soared 5.08% from the previous trading day, before settling in for the closing price of $23.80. Within the past 52 weeks, JANX’s price has moved between $22.48 and $71.71.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -54.46%. With a float of $49.57 million, this company’s outstanding shares have now reached $59.17 million.
The extent of productivity of a business whose workforce counts for 81 workers is very important to gauge. In terms of profitability, gross margin is 94.58%, operating margin of -1216.61%, and the pretax margin is -832.71%.
Janux Therapeutics Inc (JANX) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Janux Therapeutics Inc is 16.23%, while institutional ownership is 110.43%. The most recent insider transaction that took place on May 01 ’25, was worth 106,745. In this transaction Chief Business Officer of this company sold 3,333 shares at a rate of $32.03, taking the stock ownership to the 82,139 shares. Before that another transaction happened on May 01 ’25, when Company’s Officer proposed sale 3,333 for $33.20, making the entire transaction worth $110,656.
Janux Therapeutics Inc (JANX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -54.46% per share during the next fiscal year.
Janux Therapeutics Inc (NASDAQ: JANX) Trading Performance Indicators
Janux Therapeutics Inc (JANX) is currently performing well based on its current performance indicators. A quick ratio of 58.47 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 158.46.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.36, a number that is poised to hit -0.46 in the next quarter and is forecasted to reach -2.54 in one year’s time.
Technical Analysis of Janux Therapeutics Inc (JANX)
The latest stats from [Janux Therapeutics Inc, JANX] show that its last 5-days average volume of 1.3 million was superior to 1.02 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 27.38%. Additionally, its Average True Range was 1.89.
During the past 100 days, Janux Therapeutics Inc’s (JANX) raw stochastic average was set at 6.47%, which indicates a significant decrease from 52.76% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 66.20% in the past 14 days, which was lower than the 72.43% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $27.61, while its 200-day Moving Average is $41.64. Now, the first resistance to watch is $25.73. This is followed by the second major resistance level at $26.46. The third major resistance level sits at $27.62. If the price goes on to break the first support level at $23.84, it is likely to go to the next support level at $22.68. Assuming the price breaks the second support level, the third support level stands at $21.95.
Janux Therapeutics Inc (NASDAQ: JANX) Key Stats
Market capitalization of the company is 1.48 billion based on 59,175K outstanding shares. Right now, sales total 10,590 K and income totals -68,990 K. The company made 0 K in profit during its latest quarter, and -20,220 K in sales during its previous quarter.
